Immuneering prices $200 million stock offering with Sanofi participation

Immuneering Corporation (NASDAQ: IMRX) priced an underwritten public offering of 18,959,914 shares of Class A common stock at $9.23 per share, generating gross proceeds of approximately $175 million before fees and expenses, according to a company statement.

The oncology company also announced a concurrent private placement with Sanofi for 2,708,559 shares at the same price of $9.23 per share, worth $25 million. The offering price equals the last reported sale price on The Nasdaq Global Market on September 24, 2025.

Underwriters received a 30-day option to purchase up to 2,843,987 additional shares at the public offering price, less underwriting discounts and commissions. Both transactions are expected to close on or about September 26, 2025, subject to customary closing conditions.

Immuneering stated it intends to use net proceeds to advance preclinical and clinical development of its product candidates and for working capital and general corporate purposes. Leerink Partners and Oppenheimer & Co. serve as joint bookrunners for the public offering and placement agents for the private placement.

The public offering operates under a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on August 13, 2025, and declared effective August 20, 2025. The private placement shares were not registered under the Securities Act of 1933.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Sky Century Investment responds to OTC Markets stock promotion inquiry
• enVVeno Medical (NVNO) files $100M mixed shelf